O
Omniox
Omniox, a biotechnology company, commercializes technologies used in identifying and treating cancer, cardiovascular disease and trauma
About Omniox
Omniox is an IND stage biotherapeutics company focused on developing innovative H-NOX platform technology to create OMX oxygen delivery vehicles. These biologics are engineered to safely deliver oxygen to hypoxic tissues, where low oxygen levels contribute to disease progression and poor patient outcomes. By targeting and oxygenating these specific tissues, OMX biologics aim to restore normal tissue function and address significant unmet medical needs. The company operates in the biopharmaceutical market, primarily serving healthcare providers and patients with conditions related to hypoxia. Omniox's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary oxygen delivery solutions. Revenue is generated through partnerships, licensing agreements, and future product sales.
Source: Dealroom company dataAt a glance
- Founded
- 2006
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Wellcome Trust
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Omniox on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Omniox on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.